Artivion, Inc. (NYSE:AORT – Get Free Report) CEO James P. Mackin sold 42,156 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $27.31, for a total transaction of $1,151,280.36. Following the sale, the chief executive officer now owns 663,882 shares of the company’s stock, valued at approximately $18,130,617.42. This trade represents a 5.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Artivion Trading Down 0.5 %
AORT opened at $25.44 on Thursday. The company has a fifty day moving average price of $29.68 and a two-hundred day moving average price of $27.83. Artivion, Inc. has a 1-year low of $18.38 and a 1-year high of $32.33. The company has a market cap of $1.07 billion, a P/E ratio of -1,272.00 and a beta of 1.75. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71.
Artivion (NYSE:AORT – Get Free Report) last issued its earnings results on Monday, February 24th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.51). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The firm had revenue of $97.31 million during the quarter, compared to the consensus estimate of $100.82 million. Analysts predict that Artivion, Inc. will post 0.37 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
View Our Latest Research Report on Artivion
Institutional Investors Weigh In On Artivion
Hedge funds and other institutional investors have recently modified their holdings of the company. Quarry LP grew its position in Artivion by 210.8% in the 3rd quarter. Quarry LP now owns 1,209 shares of the company’s stock valued at $32,000 after purchasing an additional 820 shares during the period. Smartleaf Asset Management LLC grew its holdings in shares of Artivion by 236.7% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company’s stock valued at $32,000 after buying an additional 786 shares during the last quarter. R Squared Ltd bought a new stake in shares of Artivion during the fourth quarter worth about $39,000. Arcadia Investment Management Corp MI acquired a new stake in shares of Artivion in the 4th quarter worth about $43,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Artivion in the 4th quarter valued at about $64,000. Institutional investors own 86.37% of the company’s stock.
About Artivion
Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.
Featured Stories
- Five stocks we like better than Artivion
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Buffett’s on the Sidelines – Should You Follow?
- ESG Stocks, What Investors Should Know
- AST SpaceMobile Stock Surges 17% After Analyst Upgrade
- How to invest in marijuana stocks in 7 steps
- 3 Stocks With Triple-Digit PEs That Are Still Worth a Look
Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.